Etid klinik pou BPCO nan South Carolina
14 etid pou BPCO ap chèche patisipan nan sit nan South Carolina.
Vil nan South Carolina
Tèks ofisyèl etid la (Anglè)
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Clinical Research of Rock Hill, Rock Hill
Ap rekriteFaz 2
Laj 40 a 85 · Tout sèks · Mizajou Sep 30, 2026 · NCT07684820Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- AnMed Oglesby Center- Site Number : 8400074, Anderson
- MD First Research - Lancaster- Site Number : 8400102, Lancaster
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- MedTrial- Site Number : 8400010, Columbia
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07190222A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Lancaster
- Research Site, Spartanburg
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07082738A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Rock Hill
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06883305A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Anderson
- Research Site, Columbia
- Research Site, Gaffney
- ak 2 plis
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06878261A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Bogan Sleep Consultants, LLC, Columbia
- Velocity Clinical Research, Gaffney, Gaffney
- Clinical Research of Rock Hill, Rock Hill
- ak 1 plis
Ap rekriteFaz 2/3
Laj 35 a 80 · Tout sèks · Mizajou Aug 31, 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Anderson
- Research Site, Charleston
- Research Site, Gaffney
- ak 2 plis
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Aug 26, 2026 · NCT06283966A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 101, Charleston
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Aug 11, 2026 · NCT07555483STRIVE Post-Market Registry Study
- AnMed Health, Anderson
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT04302272eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Greenville
- GSK Investigational Site, Rock Hill
Ap rekriteFaz 3
Laj 40 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07177339Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Spartanburg
- GSK Investigational Site, Union
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Apr 9, 2026 · NCT06961214Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
- GSK Investigational Site, Rock Hill
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Oct 8, 2025 · NCT06959095Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Medical University of South Carolina (MUSC), Charleston
- McLeod Health, Florence
Ap rekriteEtid obsèvasyon
Laj 50 ak plis · Tout sèks · Mizajou Aug 5, 2025 · NCT06122077Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.